Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Celcuity Inc. seeks an Associate Director, Congress Planning to lead the strategic planning, execution and optimization of its congress program.
You will partner with Marketing, Sales, Market Access and Medical Affairs to deliver impactful experiences, manage budgets and vendors, and drive scalable processes across a growing portfolio. The role requires strong leadership, program governance and onsite execution skills, with travel as needed to congresses and events.
The Associate Director, Congress Planning is responsible for leading the strategic planning, execution, and continual optimization of Celcuity's congress program. This role serves as a key business partner across Marketing, Sales, Market Access, Medical Affairs and other cross-functional teams to deliver impactful congress experiences that enhance Celcuity's visibility, strengthen stakeholder engagement, and support corporate objectives. The Associate Director will oversee and execute the Celcuity congress program, including leading the overall planning process, project management, exhibit and event execution, agency management, budgeting, and operational excellence, while developing scalable processes and standards to support a growing portfolio of congresses.
Essential Job Functions and Responsibilities may include but are not limited to:
Required:
Preferred:
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.
Celcuity is an Equal-Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $170,000 to $180,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.